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Conventional assays of viral particle assembly and release are time consuming and laborious. We have
developed an enzymatic virus-like particle (VLP) genesis assay that rapid and quantitative and is also
versatile and applicable to diverse viruses including HIV-1 and Ebola virus. Using this assay, which has
a dynamic range of several orders of magnitude, we show that the efficiency of VLP assembly and
release, i.e., the fraction of the expressed protein that is assembled into extracellular particles, is
dependent on the absolute level of expression of either HIV-1 Gag or Ebola virus VP40. We also
demonstrate that the activity of the antiviral factor tetherin is dependent on the level of HIV-1 Gag
expression and the numbers of VLPs generated, and appears to become saturated as these parameters
are increased.
& 2012 Elsevier Inc. All rights reserved.Introduction
Virus particle assembly and release is a complex process that is
initiated by the synthesis and movement of viral structural
proteins and genomes to sites of particle assembly. Subsequently,
the virion components coalesce in an ordered manner into viral
particles and ultimately depart from the cell. These events are
often heavily influenced by host cell machinery and processes. On
the one hand the virus can usurp host cell machinery to assist in
virion assembly, while on the other, host cells have evolved
antiviral restriction factors that can inhibit the release of viral
particles.
For some viruses, including HIV-1 and Ebola virus that are the
subject of this study, examination of particle assembly and
release is facilitated by the use of experimental systems in which
a subset of viral proteins – or even a single viral protein species –
are expressed. In such instances, virus-like particles (VLPs) that
are morphologically similar to authentic virions are generated.
For retroviruses, the Gag protein is the major structural compo-
nent of particles and in most cases the expression of this protein
alone in an appropriate cellular context is sufficient to drive the
formation of extracellular VLPs (Gottlinger, 2001). Typically, Gag
proteins are comprised of the membrane binding matrix (MA)
domain as well as capsid (CA) and nucleocapsid (NC) domains
that play key roles in assembly though Gag oligomerization and
envelopment. In addition, Gag proteins contain sequences (withinll rights reserved.
).the C-terminal p6 protein in the case of HIV-1 Gag) that serve as
‘late’ (L-) domains and recruit components of the endosomal
sorting complex required for transport (ESCRT) machinery that
are required for particle budding from the cell surface (Morita and
Sundquist, 2004). In a similar manner to retroviral Gag proteins,
the matrix proteins (VP40) of the Filoviridae (e.g., Ebola virus) are
capable of generating extracellular VLPs when expressed as the
only viral protein in cultured cells (Jasenosky et al., 2001;
Timmins et al., 2001). Although retroviral Gag and filoviral VP40
proteins share this intrinsic VLP assembly property, they exhibit
no sequence or structural homology, except for their L-domains.
VP40 proteins also differ from Gag proteins in that their
L-domains are located close to their N-termini and, in contrast
to most Gag proteins, VP40 proteins can tolerate fusions at their
N-termini rather than their C-termini (Martin-Serrano et al.,
2004; Martin-Serrano et al., 2001).
When first translated, HIV-1 Gag exists primarily in mono-
meric or low order multimeric states in the cytosol (Kutluay and
Bieniasz, 2010). In Gag monomers, the N-terminal myristoyl
group exhibits a propensity to be occluded within a pocket in
the MA domain, while Gag oligomerization induces myristoyl
group exposure (Tang et al., 2004; Zhou and Resh, 1996). As such,
Gag oligomerization increases the intrinsic membrane binding
properties of each Gag monomer. This phenomenon, coupled with
the multimerization of membrane binding surfaces that occurs as
a result of Gag oligomerization, may underlie the apparent
cooperativity, or greater efficiency of particle release at higher
levels of Gag expression, that characterizes HIV-1 assembly
(Hatziioannou et al., 2005; Perez-Caballero et al., 2004). Ebola
virus VP40 (EbVP40) also exists in a primarily monomeric state in
S.S. Yadav et al. / Virology 429 (2012) 155–162156transfected or infected cells, but assembles into hexamers and/or
octamers during particle genesis (Gomis-Ruth et al., 2003;
Hartlieb and Weissenhorn, 2006; Scianimanico et al., 2000). It is
not known whether EbVP40 assembly exhibits the same coopera-
tive properties as does HIV-1 Gag.
During assembly and budding through the host plasma mem-
brane, a number of enveloped viruses, including HIV-1 and Ebola,
can encounter a host defense mechanism that inhibits particle
release (Neil et al., 2008; Van Damme et al., 2008). Tetherin is an
interferon induced host cell transmembrane protein that forms
parallel dimers and causes retention of virions by physically tether-
ing them to the host cell membrane (Fitzpatrick et al., 2010;
Hammonds et al., 2010; Perez-Caballero et al., 2009), it has broad
antiviral specificity (Jouvenet et al., 2009; Kaletsky et al., 2009;
Sakuma et al., 2009), and as a result, viruses have evolved various
mechanisms to counteract it. For example, the HIV-1 Vpu protein
antagonizes tetherin, at least in part by reducing its expression at
the cell surface (Neil et al., 2008; Van Damme et al., 2008).
Analyses of viral particle assembly and release, and its inhibi-
tion by antiviral proteins such as tetherin generally employ assays
such as western blotting, metabolic labeling, ELISA or infectivity
measurements for the detection of virions. These assays are
typically cumbersome, sometimes suffer from a lack of true
quantitation, and/or are indirect measures of particle formation.
Therefore, to facilitate direct quantitiative analyses of viral
particle assembly and release, we developed a rapid and facile
luminescence-based assay that quantifies the viral structural
proteins in cell lysates and extracellular virus-like particles,
providing a simple and direct measurement of virion assembly
and release. Specifically, we fused the a-peptide of b-galactosi-
dase to the C-terminus of the HIV-1 Gag protein and to the
N-terminus of the Ebola virus Vp40 protein. Thereafter, we
measured a-peptides in cell and virion lysates by complementa-
tion with the o-fragment of b-galactosidase and a commercial
chemiluminescent enzyme assay. The approach is marginally
superior to near-IR quantitative fluorescent western blotting in
sensitivity and dynamic range, but requires a fraction of the time
and effort. We use this assay to demonstrate that the yield of HIV-
1 and Ebola VLPs is not directly proportional to Gag or VP40
expression levels, rather the efficiency with which the viral
proteins are assembled and released as VLPs increases as protein
expression is increased. Additionally, we demonstrate that the
antiviral activity of tetherin is diminished at higher levels of Gag
expression, suggesting that it is saturable, consistent with the
notion that it acts directly to block virion particle release.Gag/Gag-α
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293T cell cultures that was present in extracellular VLPs following transfection with 500
cell lysates was determined by quantitative western blotting. The mean and stand
micrographs showing viral like particles budding from 293T cells expressing Gag or GResults
HIV-1 Gag-a is expressed and released as VLPs equivalently
to unmodified HIV-1 Gag
To attempt to quantify the assembly and release of HIV-1 VLPs,
we placed a small (6 kDa) a-peptide tag at the C-terminus of the
HIV-1 Gag protein in the context of a plasmid expressing a codon
optimized gag gene. The a-peptide is a 55-residue sequence from
the b-galactosidase enzyme and can complement the inactive o-
fragment when mixed with it, restoring b-galactosidase enzy-
matic activity. b-galactosidase can be sensitively and accurately
detected and quantitated using commercially available chemilu-
minescent substrates. We first tested whether appending HIV-1
Gag C-terminus with the a-peptide caused any changes in Gag
expression or release of VLPs. HIV-1 Gag or Gag-a proteins were
transiently expressed at varying levels (13 ng to 400 ng of
transfected plasmid DNA) in 293T cells and protein expression
and VLP release were quantitated using western blot analyses of
cell and VLP lysates with an anti-Gag antibody. The levels of
expression and particle release observed with either Gag or Gag-a
were indistinguishable (Fig. 1(A) and (B)). Moreover, the particles
that formed upon expression of Gag-a were similar in size and
morphology to those generated upon expression of unmodified
Gag (Fig. 1(C)). These results suggest that addition of the a-
peptide did not alter the overall conformation and functionality of
the HIV-1 Gag protein.
Direct measurement of HIV-1 Gag-a expression and VLP release
using b-Galactosidase assays
A commonly used method for examining HIV-1 particle
assembly and release involves western blot analysis of cell lysates
and VLPs with anti-Gag antibodies. We therefore used a quanti-
tative fluorescent western blot approach (LiCOR) as a standard
against which to assess the a-peptide based VLP assembly/release
assay. To verify that the a-peptide could be sensitively detected in
the context of a Gag fusion protein, we first serially diluted lysates
of cells expressing Gag-a and subjected replicate aliquots to b-
Galalactosidase assay and quantitative fluorescent western blot
analysis with an anti-Gag antibody (Fig. 2(A) and (B)). Results
from the two assays correlated well (Fig. 2(B)). In fact, at low
quantities of cell lysates (o0.04 ml) the chemiluminescent a-
peptide detection assay was slightly more sensitive, and thus had
a commensurately wider dynamic range, than western blotGag Gag-α
ells were transiently transfected with increasing amounts of plasmids expressing
d 48 h post-transfection and VLPs were prepared at the same time from culture
jected to SDS-PAGE and transferred onto nitrocellulose membranes. Western blots
Gag and Gag-a are released from cells is shown as the fraction of the total Gag in
ng of plasmids expressing either Gag or Gag-a. Levels of Gag or Gag-a in VLPs and
ard deviation of 7 experiments is plotted. (C) Gallery of thin-section electron
ag-a. Scale bar¼200 nm.
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Fig. 2. Characteristics of the Gag-a detection assay as compared to western blot analysis. 293T cell lysates expressing Gag-a (500 ng of transfected plasmid) were serially
diluted and subjected to western blot analysis with anti-Gag and anti-Tubulin antibodies (A, B) and also to b-galactosidase assay for a-peptides (B). Western Blots were
quantitated using the Odyssey quantitation software and intensities were assigned arbitrary units. (C) 293T cells were transfected with increasing amounts of Gag-a
expression plasmid (16 ng, 31 ng, 63 ng, 125 ng, 250 ng, 500 ng and 1000 ng) or empty vector alone. Cells were harvested 48 h post-transfection and VLPs were pelleted
through a 20% sucrose cushion. The cell lysates and VLPs were subjected to western blot analyses (probed with anti-Gag and anti-Tubulin antibodies). (D) Cell lysates and
VLPs from (C) were also assayed using the b-galactosidase assay.
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the amount of transfected plasmid DNA from 16 ng to 1000 ng) in
293T cells and assayed for a-peptides in cell lysates and VLPs. As
expected, we detected a progressive increase in the expression of
Gag-a in cell lysates as the amount of transfected Gag-a expres-
sion plasmid was increased (Fig. 2(C) and (D)). Notably, the
amount of Gag-a that was measured in VLPs increased dispro-
portionately to that in cell lysates as the amount of Gag expres-
sion plasmid was increased (Fig. 2(C) and (D)). Put another way,
the efficiency of assembly and release of HIV-1 VLPs appeared to
progressively increase as Gag expression was increased
(Fig. 2(D)). The same effect was observed whether western blot
or a-peptide assays were used to assess VLP assembly and
release.
We next sought to verify that the chemiluminscent a-peptide
assay genuinely measured VLP release by testing whether the
signal was reduced by mutations in the HIV-1 Gag p6 L-domain
that block the recruitment of ESCRT proteins required for the
efficient budding of viral particles. The wild-type Gag-a gave a
strong a-peptide signal in VLPs compared to empty vector or
untagged Gag controls (with a signal to background ratio of 4100
fold). Conversely, the L-domain mutant Gag-a protein gave
a 20-fold lower signal when VLPs were subjected to analysis
(Fig. 3(A) and (B)), even though the mutant Gag-awas expressed at
a level equivalent to WT Gag-a. Western blot assays confirmed
these results, and thus it was clear that Gag-a could assemble and
be released as VLPs in an ESCRT-protein dependent manner in the
same way as the authentic HIV-1 Gag protein.
In order to test the versatility of this approach for measuring
VLP assembly and release, we placed sequences encoding the
a-peptide at the N-terminus of Ebola virus VP40 protein. As was
the case with HIV-1 Gag, we could easily detect and quantifyEbola VLP assembly and release, (Fig. 3(C)), with signal to back-
ground ratios of 100. Similarly, mutating either the PTAP or
PPXY motifs in the VP40 L-domain (P7L or P11L) led to a decrease
of 20-fold in VLP (a-peptide) signal as compared to WT VP40-a
(Fig. 3(C)). Again, the results obtained using the chemilumines-
cent assay were concordant with those obtained by western Blot
(Fig. 3(D)) and with previous reports (Martin-Serrano et al., 2001).
However, the chemiluminsecent assay was more rapid and
allowed the residual VLP release observed with the L-domain
mutant to be detected and quantified (Fig. 3(C)).
Cooperativity in HIV-1 and Ebola VLP assembly
The apparently disproportionate increase in the level of VLP-
associated a-peptides as Gag-a expression was increased
(Fig. 2(C) and (D)) is consistent with the notion that assembly
of Gag proteins and generation of VLPs is cooperative. To
demonstrate this property more definitively, we expressed a fixed
amount of Gag-a alone, or with an increasing amount of untagged
Gag. If the probability that individual molecule of Gag is incorpo-
rated into a VLP is increased by the presence of other molecules of
Gag, then the level of Gag-a molecules in VLPs should increase as
untagged Gag levels are increased, even if the level of expression
of Gag-a is held constant. In fact, as expression of untagged Gag
was increased, the fraction of Gag-a that was released in VLPs
was increased (Fig. 4(A) and (B)). We next tested whether the
assembly Ebola VP40 molecules into VLPs exhibited similar
cooperative properties. For this, we expressed a fixed amount of
VP40-a in the absence or presence of an increasing concentration
of untagged VP40. As was the case for HIV-1 Gag, we observed an
increase in the efficiency of VP40-a incorporation into extracel-
lular particles as the levels of untagged VP40 were increased
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Fig. 3. Verification that the a-peptide/b-galactosidase assay measures bona fide HIV-1 release and can also be applied to Ebola virus. (A) and (B) 293T cells were
transiently transfected with 500 ng of plasmids expressing either Gag, Gag-a or GagdL-a. After 48 h cell lysates and VLPs were subjected to b-galactosidase assay (A) and
western blot analysis (B) with anti-Gag and anti-Tubulin antibodies. Graphs represent mean and standard deviation of three experiments. (C) and (D) 293T cells were
transiently transfected with 500 ng of plasmids expressing either Ebola virus VP40, VP40-a, VP40-a (P7L) or VP40-a (P11L). After 48 h cell lysates and VLPs were subjected
to b-galalactosidase assay (C) and western blot analysis (D) with anti-Myc and anti-Tubulin antibodies. Graphs represent mean and standard deviation of two experiments.
S.S. Yadav et al. / Virology 429 (2012) 155–162158(Fig. 4(C) and (D)). In addition, the untagged VP40 appeared to
marginally increase the levels of VP40-a protein that were
detected in cells, suggesting the possibility that VP40 acquires
greater stability as it is assembled into particles within cells. Thus,
concentration dependence might be a general characteristic of the
assembly of diverse enveloped virus structural proteins.
Tetherin is a saturable host cell restriction factor
Tetherin is a host antiviral protein whose expression leads to
the retention of virion particles by infected cells and inhibition of
viral dissemination. Current models of the mechanism by which
tetherin functions invoke a scenario in which the tetherin proteindirectly blocks particle release via the action of two membrane
anchors that partition between the virion and host cell mem-
branes. If this model is correct, then increasing the expression of
Gag to a sufficiently high level might saturate the available
tetherin, facilitating particle release. The development of a rapid
quantitative VLP release assay with a large dynamic range
provided an opportunity to easily investigate this question.
Therefore, we examined the ability of varying levels of tetherin
to inhibit particle release at high and low levels of HIV-1 Gag-a
expression (200 ng or 25 ng of transfected Gag-a expression
plasmid, respectively, Fig. 5). When the higher amount of Gag-a
was expressed, tetherin was clearly less effective at inhibiting
particle release than when lower levels of Gag-a were expressed
Tubulin- C
el
l L
ys
at
e
V
LP
s
Gag-α-
Gag-α-
Gag-
Gag-
VP40-α-
VP40-
C
el
l L
ys
at
e
VL
Ps
Tubulin-
VP40-α-
VP40-
25
0
12
5
50250
50
0
0
12
5
Gag
expression 
Plasmid
(ng)
VP40
expression 
Plasmid
(ng)
Gag
VP40
Fig. 4. Cooperativity in HIV-1 and Ebola virus particle assembly/release. (A) and (B) 293T cells were transfected with a fixed amount (25 ng) of a Gag-a expression plasmid
along with increasing amounts (0 ng, 25 ng, 50 ng and 125 ng) of a plasmid expressing untagged Gag. Cells and VLPs were subjected to western blot analysis with anti-Gag
and anti-Tubulin antibodies (A) and b-galactosidase assay (B). (C) and (D) 293T cells were transfected with a fixed amount (50 ng) of a plasmid expressing VP40-a along
with increasing amounts (0 ng 125 ng, 250 ng and 500 ng) of plasmid expressing untagged VP40. Cells and VLPs were subjected to western blot analysis with anti-Myc and
anti-Tubulin antibodies (C) and b-galactosidase assay (D).
S.S. Yadav et al. / Virology 429 (2012) 155–162 159(compare Fig. 5(A) and (B) with Fig. 5(C) and (D)). Indeed, at lower
levels of Gag-a expression, only 10–20 ng of cotransfected
tetherin expression plasmid was required to inhibit particle
release by 10-fold (Fig. 5(E)). Conversely, 200 ng of cotransfected
tetherin expression plasmid was required to achieve the same
level of inhibition when the higher level of Gag-a was expressed
(Fig. 5(A) and (B)).Discussion
The lack of a rapid and quantitative system to specifically
measure the assembly and release of viral particles is a significant
inconvenience in studies of this process. Therefore, we set out to
develop a novel assay to detect VLP formation sensitively,
quantitatively and accurately, in experiments involving many
samples, and in a significantly shorter time (2 h) compared to
other conventional methods (1–2 day). As expression of retro-
virus Gag and filovirus VP40 proteins is sufficient for the assem-
bly of bonafide extracellular VLPs, placing an easily quantifiable
tag on them enabled direct quantification of expression and VLP
assembly. We decided to use a small 55 amino acid a-peptide
from b-galactosidase enzyme as the tag. This has at least two
advantages. First, the tag is small (6 kDa) and should, therefore, be
less likely to cause major changes in the folding of virals proteins
and assembly into VLPs. This prediction proved accurate;
a-peptide tagged HIV-1 Gag and Ebola VP40 proteins assembledinto extracellular particles as efficiently as untagged counterparts.
Second, the tagged protein could be quantified using a very
simple a-complementation assay which dramatically reduced
the time and effort required to measure VLP generation. Overall,
the assay fulfilled the desired criteria.
Previously, few other studies have described luminescence-based
assays of modified viral proteins to study viral assembly. In one such
study, firefly luciferase was fused to EbVP40, but the fusion protein
was not enzymatically active in VLPs (McCarthy et al., 2006). In
another study Gaussia luciferase was fused to the C-terminus of the
Z-protein of Lassa virus but the signal to noise ratio in that assay
was only 8-fold (Capul and de la Torre, 2008). Others have
reported the use of an HIV-1 Gag-luciferase fusion protein to study
particle formation in yeast (Sakuragi et al., 2006). However, chemi-
luminescent signals obtained from this protein were very low,
consistent with our own experience that HIV-1 Gag-Luciferase
fusion proteins are poorly incorporated into VLPs in mammalian
cells (unpublished observations). Recently, a Vpr-firefly luciferase
fusion has been used to monitor HIV-1 particle release in a
baculovirus-based Gag and Vpr expression system (Gonzalez et al.,
2011). However, this is obviously a non-native context, with highly
overexpressed Gag and Vpr proteins. Finally, the a-peptide has
previously been inserted at an internal location in the HIV-1 Gag
protein in order to monitor proteolytic processing (Jochmans et al.,
2010). Overall, this report is the first time that a direct enzyme
based quantification of viral structural proteins has been used to
monitor viral particle assembly and release in mammalian cells.
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can be used to study the assembly and release of two unrelated
viruses, namely Ebola and HIV-1 (Fig. 3). Moreover, it has a large
dynamic range (two to three orders of magnitude) and has compar-
able sensitivity to western blot analysis (Fig. 2(A) and (B)). We could
directly quantify the effect of L-domain mutations on particle
release, further demonstrating the utility and authenticity of the
measurements. We applied this rapid assay to investigate two
aspects of viral particle assembly and release in a quantitative
manner. First, it has been previously shown that the assembly of
HIV-1 Gag protein into particles is more efficient (i.e., a greater
fraction of Gag found in extracellular virions as opposed to cells)
when Gag is expressed at higher levels (Hatziioannou et al., 2005;
Perez-Caballero et al., 2004). We quantified this phenomenon in two
ways. First, by increasing the level of HIV-1 Gag-a expression, we
found that the fraction of Gag-a that was found in VLPs could be
increased by up to 5-fold (Fig. 2(C) and (D)). Second, by holding the
level of Gag-a constant and increasing the level of unmodified Gag,
the fraction of Gag-a that was incorporated into virions could be
increased by 3.5 fold. (Fig. 4(A) and (B)). A similar effect was seen for
Ebola virus VP40, where an increase in intracellular concentration of
unmodified VP40 lead to an approximately 10-fold increase in the
fraction of the a-VP40 protein that was present in extracellular
VLPs. This apparent cooperativity in the generation of VLPs upon
enhanced expression of viral structural proteins in viruses as diverse
as HIV-1 Gag or Ebola virus VP40 suggests the possibility that it
might be a general phenomenon. The mechanistic underpinning of
this effect would likely lie in increased multimer formation as a
consequence of increased viral protein concentration. Such multi-
merization of viral proteins could result in conformation changes
that increase the intrinsic affinity of each viral protein monomer for
other monomers, or (in the case of enveloped viruses) the affinity of
each monomer for membranes. Alternatively, it is possible that
multimerization of proteins with weak membrane binding proteins
could result in complexes with higher membrane binding avidity. Inthe case of HIV-1, it appears that the intrinsic membrane binding
affinity of Gag is regulated by multimerization, in part due to the
presence of a myristoyl switch, whereby the N-terminal myristate is
preferentially concealed in a hydrophobic pocket in the monomeric
state, and exposed in the multimeric state (Tang et al., 2004).
A second way in which viral structural protein expression
levels can affect the efficiency with which extracellular particles
are generated occurs as a consequence of the expression of the
antiviral protein, tetherin. Recent studies have shown that
tetherin is incorporated into the lipid envelope of HIV-1 particles
and is directly responsible for virion tethering to the plasma
membranes (Fitzpatrick et al., 2010; Perez-Caballero et al., 2009).
Using the assay developed herein, we could precisely quantitate
the reduction in physical particle yield attributable to tetherin
expression, and demonstrate that tetherin can be saturated by
increasing the expression of HIV-1 Gag. Indeed, the ability of
tetherin to inhibit HIV-1 particle production varied dramatically
according to the level at which the HIV-1 Gag protein was
expressed. The saturability of tetherin and its alleviation by
increasing the level of tetherin expression provide further support
to the notion that tetherin acts by directly tethering virions on the
cell surface.
Because the efficiency of particle assembly/release can, in part,
be determined by the expression level of viral structural proteins,
caution is warranted in interpreting data in which manipulations
that affect particle yield also affect viral protein expression levels.
Often, investigators ‘normalize’ measurements of extracellular viral
particle yield to viral protein expression level in cells to obtain a
measurement of particle formation efficiency. However, the findings
reported herein suggest that experimental manipulations that only
alter viral protein expression levels can also alter the intrinsic
efficiency of virion assembly and release, leading to misleading
conclusions if data is normalized in the aforementioned way.
In conclusion, we have developed a quantitative, sensitive and
easily performed assay to study particle formation of two diverse
S.S. Yadav et al. / Virology 429 (2012) 155–162 161viruses. The assay principle should be broadly applicable to
studies of the assembly of many viruses, and with slight mod-
ifications might be amenable to high throughput screening. It
provides a potentially valuable tool for understanding the com-
plex process of virion assembly and a possible approach to rapidly
screen for chemical inhibitors of viral assembly and release as
potential therapeutics.Materials and methods
Plasmids
To generate plasmids expressing a-peptide tagged HIV-1 Gag
proteins (Gag-a), sequences encoding the 55-residue a-peptide
of b-galactosidase (MSSNSLAVVLQRRDWENPGVTQLNRLAAHPP-
FASWRNSEEARTDRPSQQLRSNLGE) were amplified, using PCR, from
the plasmid, pProLabel-N (Clontech). This sequence was inserted at
the 3’ end of HIV-1 Gag coding sequences in place of GFP in
pCR3.1SynGag-GFP or an an L-domain mutant thereof (pCR3.1Syn-
GagLD-GFP) between the NotI and XhoI sites (Perez-Caballero et al.,
2004). To generate plasmids expressing N-terminally a-peptide
tagged Ebola virus VP40 protein (VP40-a) and a corresponding
L-domain mutant (P7L and P11L), the same sequence was inserted
into pCR3.1MycEbVP40 (Martin-Serrano et al., 2004) between EcoRI
and BamHI sites. Plasmids expressing Tetherin-HA and Vpu-HA have
been described previously (Jouvenet et al., 2009; Neil et al., 2006).
Integrity of all the constructs were confirmed by restriction diges-
tion and sequencing.
Chemiluminescent VLP release assay
293T cells were maintained in Dulbecco’s Modified Eagle
Medium supplemented with 10% fetal bovine serum and genta-
mycin. For virus release assays, cells were seeded at 1105 cells/
well in 24-well plates and transfected using polyethyleneimine
(PEI) at a DNA:PEI ratio of 1:4. At 48 h post-transfection super-
natants were collected and clarified by centrifugation at 1000 rpm
for 5 min. The cleared supernatants (350–400 ml) were filtered
(0.2 mm), layered over 600 ml of 20% sucrose in 1X PBS and
centrifuged at 14,000 rpm in an Eppendorf 5417R microfuge for
90 min at 4 1C. The pellets containing viral like particles (VLPs)
were resuspended in 1X Reporter Lysis Buffer (NEB Cat. No.
B3321S). Cell lysates were prepared by incubating the cells in
1X lysis buffer with rocking for 30 min at room temperature. VLPs
and cell lysates were subjected to cheminluminescent b-galacto-
sidase assay for a-peptides according to manufacturer’s instruc-
tions (ProLabel Detection kit, Clontech). The reactions were
developed for 1 h at room temperature in the dark and lumines-
cence was read using a luminometer (Dynex technologies).
Western blot analyses
Cell lysates and VLPs were separated on 4–12% acrylamide gels
(Novex) and proteins transferred to nitrocellulose membranes
which were then probed with antibodies against HIV-1 Gag (183-
H12-5C), tubulin (Santa Cruz), and the HA (Santa Cruz) or Myc
(9E10) epitope tags. The blots were then probed with appropriate
IR Dye (680 or 800 CW, LiCOR) conjugated secondary antibodies.
The blots were scanned using the LICOR Odyssey IR imager and
signals quantified using the Odyssey quantification software.
Electron microscopy
293T cells were transfected with plasmids expressing Gag or
Gag-a (5 mg) along-with a plasmid expressing GFP (0.5 mg) usingPEI. Forty hours later cells were harvested and fixed with 2%
paraformaldehyde and 2.5% glutaraldehyde in 0.1 M cacodylate
buffer (0.1 M sodium cacodylate [pH 7.4], 35 mM sucrose, 4 mM
CaCl2). The cells were first stained with 1% OsO4 and 1% K4FeCN6
in 0.1 M cacodylate buffer and dehydrated with 50% ethanol. After
subsequent staining with 2% uranyl acetate in 70% ethanol the
cells were dehydrated in graded ethanol (70–100%) and
embedded in epoxy resin (Electron Microscopy Sciences). Thin
sections were stained with uranyl acetate. Electron micrographs
were taken on a transmission electron microscope (FEI TECNAI G2
Spirit BioTwin Transmission Electron).Acknowlegments
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